

# Brigham and Women's Hospital PGY2 Demonstration Residency in Thrombosis and Hemostasis Management

## BWH Hospital and Pharmacy Department Overview

Brigham and Women's Hospital, located in Boston's Longwood Medical Area, is a nearly 900-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Mass General Brigham. BWH was named among the top 20 hospitals in the United States by US News & World Report's Honor Roll of America's Best Hospitals 2024-2025. The Department of Pharmacy provides services to inpatient, outpatient, and satellite clinic locations throughout the Metro Boston area. The department is regarded as an innovator and leader in medication safety technology, clinical information systems, and clinical pharmacy services at the local and national level.





#### **Background**

Management of anticoagulation and hemostasis continues to evolve with increasing complexity, risk, cost, and accreditation standards. Pharmacists play pivotal roles in thrombosis and hemostasis management and in the implementation and operation of successful multidisciplinary anticoagulation stewardship programs.

#### **General Information**

The goal of this PGY2 Thrombosis and Hemostasis Residency is to fully prepare licensed pharmacists to practice in a variety of roles that oversee anticoagulation and hemostasis management including inpatient anticoagulation and hemostasis consult services, outpatient anticoagulation management services, and anticoagulation and hemostatic stewardship programs. Given the expansion in the field of anticoagulation and the growth in anticoagulation stewardship programs, it is expected that the job market will continue to expand for pharmacists with training and expertise in Thrombosis and Hemostasis Management. Completion of this residency will be a distinguishing factor in the recruitment and hiring process for such individuals.

#### **Program Fundamentals**

The PGY2 pharmacy residency programs build on Doctor of Pharmacy (Pharm.D.) education and PGY1 pharmacy residency programs to contribute to the development of clinical pharmacists in advanced or specialized practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge and incorporating both into the provision of patient care that improves medication therapy. Residents who successfully complete an accredited PGY2 pharmacy residency should possess competencies that qualify them for clinical pharmacist and/or faculty positions and position them to be eligible for attainment of board certification in the specialized practice area (when board certification for the practice area exists).

Over the course of the year, the resident will gain experience in the management of patients requiring prevention and treatment of thrombosis and bleeding, lead a comprehensive research project, strengthen communication skills through formal and informal presentations and interactions with other healthcare providers in a variety of settings, and participate in thrombosis/hemostasis and pharmacy-related interdisciplinary hospital committees. In addition, the resident will enhance their teaching skills by precepting pharmacy practice residents and students on clinical rotations. Residents will rotate through required learning experiences in addition to 1-2 elective learning experiences. The resident will also complete the ASHP Anticoagulation Certificate training. Estimated stipend: ~\$65,900/year in addition to fringe benefits such as paid time off (sick/holiday/vacation), health/life insurance, travel reimbursement/meeting fees for one conference), and reimbursement for BCPS/CACP (if passed).

For additional information on resident learning experiences, additional required activities, and other specificprogram details please see the <a href="Pharmacy Residency Manual">Pharmacy Residency Manual</a> or check us out on Twitter <a href="@BrighamPharmacy">@BrighamPharmacy</a>.

Required PGY2 Thrombosis and Hemostasis Learning Activities	Elective Learning Activities	Longitudinal Activities
<ul> <li>Orientation</li> <li>Advanced Integrated Clinical Pharmacy Practice</li> <li>Anticoagulation Management Service (AMS)</li> <li>Special Coagulation Laboratory and Benign Hematology</li> <li>Coronary Care ICU</li> <li>Cardiac Surgery ICU</li> <li>Emergency Medicine</li> <li>Hemostatic Antithrombotic Stewardship (HAT) I</li> <li>Hemostatic Antithrombotic Stewardship (HAT) II</li> <li>Medication Safety and Pharmacy Leadership</li> <li>Neuroscience ICU</li> <li>Elective</li> </ul>	To be determined annually after discussion with resident and program leadership	<ul> <li>Research</li> <li>Formal Presentations and Departmental Contributions</li> <li>Committee Responsibilities</li> <li>Staffing and Anticoagulation Management Service</li> </ul>

ICU: intensive care unit

All required rotations are 4 weeks in length, except for Special Coagulation Laboratory and Benign Hematology which is a 5-week learning experience. All longitudinal rotations will span the 52-week residency year and specific time commitments are noted within the learning descriptions.

equirer rogram	nents for Successful Completion of the PGY2 Thrombosis and Hemostasis Residency
	Successfully licensed as a practicing pharmacist in the state of Massachusetts within 120 days from the start date.
	Successful completion of program and department orientation as appropriate per resident track (internal vs external residents) as defined in learning experience description
	<ul> <li>Successful completion of all required rotation learning experiences</li> <li>Orientation</li> <li>Advanced Integrated Clinical Pharmacy Practice</li> <li>Anticoagulation Management Service (AMS)</li> <li>Special Coagulation Laboratory and Benign Hematology</li> <li>Coronary Care ICU</li> <li>Cardiac Surgery ICU</li> <li>Emergency Medicine</li> <li>Hemostatic Antithrombotic Stewardship (HAT) I</li> <li>Hemostatic Antithrombotic Stewardship (HAT) II</li> <li>Medication Safety and Pharmacy Leadership</li> <li>Neuroscience ICU</li> <li>Elective</li> </ul>
	Successful completion of 1 (external candidates) or 2 (internal candidates) elective learning experience(s)
	<ul> <li>Successful completion of all required longitudinal learning experiences</li> <li>Staffing and Anticoagulation Management Service</li> <li>Formal Presentations and Departmental Contributions</li> <li>Committee Responsibilities</li> <li>Research</li> </ul>
	Successfully document the completion of all assigned disease states in the resident topic discussion spreadsheet
	<ul> <li>Successfully reached 80% Achieved for Residency with required objectives</li> <li>Must include required objectives (R1.1.1, R1.1.3, R1.1.4, R1.1.5, R1.1.6, R1.2.1, R1.3.1, R2.1.2, R2.1.3, R2.3.6, R3.1.1, R3.2.2, R4.1.2)</li> </ul>
	<ul> <li>Successful completion of required formal presentations</li> <li>Continuing education program</li> <li>In-service ad hoc during rotation(s)</li> <li>Pharmacist Huddle - #5</li> <li>Submission of clinical pearl to a local, regional, or national conference</li> <li>Successful presentation/submission for presentation of year-long project</li> </ul>
	<ul> <li>Successful completion of professional practice requirements (staffing)</li> <li>Completion of Advanced Integrated Clinical Pharmacy Practice and weekend staffing requirements</li> </ul>

Documentation of moonlighting and duty hours as appropriate in PharmAcademic
 Documentation of Benefit Time/Time off in PharmAcademic

<ul> <li>Successful completion of Medication Policy Requirements</li> <li>At least one written drug administration guideline (DAG) and/or IV push guideline prepared for DAG Committee Review and presented at a Pharmacy and Therapeutics Committee as appropriate</li> <li>Publication in the Pharmacy and Therapeutics Committee Newsletter</li> </ul>
<ul> <li>Successful completion of all required documentation</li> <li>Initial assessment</li> <li>Quarterly self-assessment as part of the Resident Development Plan</li> <li>All learning experience and preceptor and learning experience evaluations</li> <li>Final assessment of residency and feedback</li> <li>Completion of electronic residency binder with all required documents uploaded into the THM Binders folder</li> </ul>
Other requirements

- o Obtained both Basic Life Support certification and Advanced Cardiac Life support by the end of the residency year.
- o Completion of Program Appendix
- o Completion of ASHP Anticoagulation Certificate Program

### **2024-2025 BWH PGY2 Thrombosis and Hemostasis Management Residents**



Hamza Sinan, PharmD
PGY1: Cooley Dickinson Hospital – Northampton, MA



Daniel Cartagena-Sergenian, PharmD
PGY1: The Hospital of the University of Pennsylvania
— Philadelphia, PA

## Thrombosis and Hemostasis Management PGY2 Residency Leadership Team



Residency Program Director
Katelyn Sylvester PharmD, BCPS, CACP
Ambulatory and Antithrombotic
Clinical Pharmacy Manager
Ksylvester3@bwh.harvard.edu



Residency Program Coordinator
Dareen Kanaan PharmD, MPH, BCCP
Clinical Pharmacy Specialist
dkanaan@bwh.harvard.edu